WO2011044434A3 - A composition and a method of treating cns disorders and hyperpigmentation - Google Patents
A composition and a method of treating cns disorders and hyperpigmentation Download PDFInfo
- Publication number
- WO2011044434A3 WO2011044434A3 PCT/US2010/051934 US2010051934W WO2011044434A3 WO 2011044434 A3 WO2011044434 A3 WO 2011044434A3 US 2010051934 W US2010051934 W US 2010051934W WO 2011044434 A3 WO2011044434 A3 WO 2011044434A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hyperpigmentation
- cns disorders
- hydroxychavicol
- treating cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a method of treating CNS disorders, particularly Alzheimer's disease. The method comprise step of administering to a subject in need thereof a therapeutically effective amount of hydroxychavicol and/or its derivatives or a composition comprising hydroxychavicol and/or its derivatives optionally along with pharmaceutically acceptable excipients. The invention also relates to use of hydroxychavicol and/or its derivatives for treating hyperpigmentation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25010609P | 2009-10-09 | 2009-10-09 | |
US61/250,106 | 2009-10-09 | ||
US12/900,727 US20120088841A1 (en) | 2010-10-08 | 2010-10-08 | Composition and a method of treating cns disorders and hyperpigmentation |
US12/900,727 | 2010-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011044434A2 WO2011044434A2 (en) | 2011-04-14 |
WO2011044434A3 true WO2011044434A3 (en) | 2011-08-18 |
Family
ID=43857406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/051934 WO2011044434A2 (en) | 2009-10-09 | 2010-10-08 | A composition and a method of treating cns disorders and hyperpigmentation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011044434A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012131717A2 (en) * | 2011-03-29 | 2012-10-04 | Council Of Scientific & Industrail Research | 2',3'-epoxypropyl-3.4-dihydroxy benzene and a process for the preparation thereof |
TWI699215B (en) * | 2018-08-03 | 2020-07-21 | 大江生醫股份有限公司 | Bioactive ingredients for neuroprotection and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157204A1 (en) * | 1998-04-16 | 2003-08-21 | Enrovita A/S | Novel synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga |
-
2010
- 2010-10-08 WO PCT/US2010/051934 patent/WO2011044434A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157204A1 (en) * | 1998-04-16 | 2003-08-21 | Enrovita A/S | Novel synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga |
Non-Patent Citations (6)
Title |
---|
GILANI ET AL.: "Presence of cholinomimetic and acetylcholinesterase inhibitory constituents in betel nut", LIFE SCIENCES, vol. 75, no. IS. 20, 1 October 2004 (2004-10-01), pages 2377 - 2389, XP004551452, DOI: doi:10.1016/j.lfs.2004.03.035 * |
JENG ET AL.: "Reactive oxygen species are crucial for hydroxychavicol toxicity toward KB epithelial cells", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 61, no. IS.1, 24 January 2004 (2004-01-24), pages 83 - 96 * |
KANG ET AL.: "gamma.-Secretase Inhibitor Reduces Allergic Pulmonary Inflammation by Modulating Th1 and Th2 Responses", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 179, no. IS. 10, 15 May 2009 (2009-05-15), pages 875 - 882, XP055120487, DOI: doi:10.1164/rccm.200806-893OC * |
PANDEY ET AL.: "Hydroxychavicol inhibits immune responses to mitigate cognitive dysfunction in rats", JOURNAL OF NEUROIMMUNOLOGY, vol. 226, no. 1-2, 14 September 2010 (2010-09-14), pages 48 - 58, XP027265546 * |
PANDEY ET AL.: "Modulation of Th1/Th2 cytokines and inflammatory mediators by hydroxychavicol in adjuvant induced arthritic tissues,°", CYTOKINE, vol. 49, no. IS. 1, 25 September 2009 (2009-09-25), pages 114 - 121, Retrieved from the Internet <URL:Miww.ncbi.nlm.nih.gov/pubmed/19782577j> * |
SCHWARZ ET AL.: "T-helper-1 and T-helper-2 Responses in Psychiatric Disorders", BRAIN, BEHAVIOR, AND IMMUNITY, vol. 15, 2001, pages 340 - 370, XP002271624, DOI: doi:10.1006/brbi.2001.0647 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011044434A2 (en) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264796B (en) | 6,23-substituted bile acid derivatives, pharmaceutically acceptable compositions and compounds for use in a method of treating or preventing a disease | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
WO2008052044A3 (en) | Use of derivatives of propofol for treating diseases associated with oxidative stress | |
WO2007022408A3 (en) | Combination methods of saha and targretin for treating cancer | |
MX2009010407A (en) | Fluorinated derivatives of deferiprone. | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2010114824A8 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
WO2012082718A3 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
WO2009109616A8 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 | |
EP2091566A4 (en) | Combination treatments for alzheimer's disease and similar diseases | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2011014825A3 (en) | Antiangiogenic small molecules and methods of use | |
WO2008085875A3 (en) | R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) | |
WO2013085849A3 (en) | Sulfate esters of noribogaine | |
WO2009035634A3 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors | |
SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
WO2010030976A3 (en) | Methods and compositions for inhibiting atherosclerosis and vascular inflammation | |
WO2010041252A3 (en) | Use of a cinnamon bark extract for treating amyloid-associated diseases | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
WO2011044434A3 (en) | A composition and a method of treating cns disorders and hyperpigmentation | |
WO2010004031A3 (en) | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10822748 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 10822748 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |